Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies

被引：14

作者：

Haas, C ^{[1
]}

Schirrmacher, V ^{[1
]}

机构：

[1] GERMAN CANC RES CTR, TUMOR IMMUNOL PROGRAM 0710, D-69121 HEIDELBERG, GERMANY

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1996年 / 43卷 / 03期

关键词：

Newcastle disease virus (NDV); bispecific antibodies; hemagglutinin-neuraminidase; T cell activation;

D O I：

10.1007/s002620050321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A new type of cancer vaccine for therapeutic application in cancer patients is described. It consists of three components. (1) autologous tumor cells, (2) Newcastle Disease Virus (NDV), to be used for infection and (3) bispecific antibodies (bsAb) which attach to the viral hemagglutinin neuraminidase (HN) molecule on the infected tumor cells. A standardized procedure has been developed for generating virus infected human autologous tumor cell vaccines (ATV-NDV) which includes cell dissociation, removal of leukocytes and cell debris, gamma-irradiation and cryopreservation. Infection with the non-virulent strain NDV Ulster is performed within 30 min of co-incubation. While virus infection already increased immunogenicity of the tumor vaccine, further augmentation of T cell stimulatory capacity is achieved by attachment of specially designed bi-specific antibodies (bs HN x CD28 or bs HN x CD3).

引用

页码：190 / 194

页数：5

共 43 条

[11] ADJUVANT ACTIVE SPECIFIC IMMUNOTHERAPY FOR HUMAN COLORECTAL-CANCER - 6.5-YEAR MEDIAN FOLLOW-UP OF A PHASE-III PROSPECTIVELY RANDOMIZED TRIAL [J].

HOOVER, HC ;

BRANDHORST, JS ;

PETERS, LC ;

SURDYKE, MG ;

TAKESHITA, Y ;

MADARIAGA, J ;

MUENZ, LR ;

HANNA, MG .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :390-399

[12]

JURIANZ K, 1995, INT J ONCOL, V7, P539

[13] PERSISTENCE OF DORMANT TUMOR-CELLS IN THE BONE-MARROW OF TUMOR CELL-VACCINATED MICE CORRELATES WITH LONG-TERM IMMUNOLOGICAL PROTECTION [J].

KHAZAIE, K ;

PRIFTI, S ;

BECKHOVE, P ;

GRIESBACH, A ;

RUSSELL, S ;

COLLINS, M ;

SCHIRRMACHER, V .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7430-7434

[14]

KRUGER A, 1994, BLOOD, V84, P3166

[15] SCATTERED MICROMETASTASES VISUALIZED AT THE SINGLE-CELL LEVEL - DETECTION AND RE-ISOLATION OF LACZ-LABELED METASTASIZED LYMPHOMA-CELLS [J].

KRUGER, A ;

SCHIRRMACHER, V ;

VONHOEGEN, P .

INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (02) :275-284

[16] INVITRO AND CLINICAL CHARACTERIZATION OF A NEWCASTLE-DISEASE VIRUS-MODIFIED AUTOLOGOUS TUMOR-CELL VACCINE FOR TREATMENT OF COLORECTAL-CANCER PATIENTS [J].

LIEBRICH, W ;

SCHLAG, P ;

MANASTERSKI, M ;

LEHNER, B ;

STOHR, M ;

MOLLER, P ;

SCHIRRMACHER, V .

EUROPEAN JOURNAL OF CANCER, 1991, 27 (06) :703-710

[17]

LIVINGSTON P, 1993, ANN NY ACAD SCI, V690, P1

[18]

LIVINGSTON PO, 1993, ANN NY ACAD SCI, V690, P204

[19] ASSOCIATION OF HLA PHENOTYPE WITH RESPONSE TO ACTIVE SPECIFIC IMMUNOTHERAPY OF MELANOMA [J].

MITCHELL, MS ;

HAREL, W ;

GROSHEN, S .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1158-1164

[20] TUMOR-CELL VACCINATION FOR GYNECOLOGICAL TUMORS [J].

MOBUS, V ;

HORN, S ;

STOCK, M ;

SCHIRRMACHER, V .

HYBRIDOMA, 1993, 12 (05) :543-547

← 1 2 3 4 5 →